ESR1 and breast cancer: Our results showed that the estimated IC50 values of all three drugs were significantly higher in high-risk tumors than in low-risk tumors (p < 0.001), suggesting that ER+ BC patients with higher risk scores are more resistant to cytotoxic chemotherapy (Figures 6A–C).